- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00576979
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving IMRT together with chemotherapy before transplant may stop this from happening.
PURPOSE: This phase I/II trial is studying the side effects and best dose of intensity-modulated radiation therapy (IMRT) when given together with etoposide and cyclophosphamide followed by donor stem cell transplant and to see how well they work in treating patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES: I. To establish the maximum tolerated dose [MTD] of large field image-guided IMRT, using helical tomotherapy when given in combination with intravenous cyclophosphamide and VP-16 as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) from an human leukocyte antigen (HLA)-identical sibling or unrelated donor in patients with ALL or AML with induction failure or in relapse. (Phase I) II. To describe the toxicity at each dose level standard. (Phase I) III. To collect data on the radiation dose to normal organs and bone marrow using tomotherapy targeted total-body irradiation (TBI). (Phase I) IV. To estimate the overall survival probability, disease free survival probability and relapse rate associated with this regimen. (Phase II) V. To characterize the treatment related mortality and toxicity profile (early/late) associated with this regimen. (Phase II) VI. To descriptively compare the outcomes of patients treated on this protocol to a comparable patient population conditioned with whole body radiation. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of intensity-modulated radiation therapy (IMRT) followed by a phase II study.
PREPARATIVE REGIMEN: Patients undergo IMRT using helical tomotherapy once or twice daily on days -10 to -6 or -10 to -7. Patients also receive etoposide intravenously (IV) on day -6 or -5 and cyclophosphamide IV on day -4 or -3.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day -1 or day 0. After completion of study treatment, patients are followed up periodically for up to 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with acute lymphocytic leukemia or acute myelogenous leukemia who are not in first or second remission (i.e., after failing remission induction therapy or in relapse or beyond second remission)
- All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR, or DQ and a KIR mismatch at C will be allowed; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques
- Prior therapy with VP-16, Busulfan, and Cytoxan is allowed
- A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi gated acquisition scan (MUGA) or echocardiogram
- Patients must have a serum creatinine of less than or equal to 1.2 or creatinine clearance > 80 ml/min
- A bilirubin of less than or equal to 1.5
- Serum glutamic oxaloacetic transaminase (SGOT) less than 5 times the upper limit of normal
- Serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
- Pulmonary functioning tests including diffusing capacity of carbon monoxide (DLCO) will be performed; forced expiratory volume in one second (FEV1) and DLCO should be greater than 50% of the predicted normal value
- The time from the end last induction or reinduction attempt should be >= 14 days
- Signed informed consent form approved by the Institutional Review Board (IRB) is required
DONOR: Any sibling donors who are histocompatible with the prospective recipient will be considered a suitable donor
- Donors will be excluded if for psychological or medical reasons they are unable to tolerate the procedure
- Donor should be able to donate peripheral blood stem cells or bone marrow
Exclusion Criteria:
- Prior radiation therapy that would exclude the use of total-body irradiation
- Patients who have undergone bone marrow transplantation previously and who have relapsed
- Patients with psychological or medical condition that patients physician deems unacceptable to proceed to allogeneic bone marrow transplant
- Pregnancy
- Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Level 1: 1200cGy
150cGy BID x Days 1-4.
Total dose 1200cGy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 2: 1350cGy
150cGy BID Day 1-4 then 150 cGy QD Day 5. Total dose 1350cGy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 3: 1500cGy limited dose to ribs, sternum, liver, brain 1200cGy
150cGy BID Day 1-5.
Total dose 1500Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 4: 1500cGy limited dose to liver, brain 1200cGy
150cGy BID Day 1-5.
Total dose 1500Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 5: 1600cGy limited dose to liver, porta-hepatic, brain 1200cGy
160cGy BID Day 1-5.
Total dose 1600Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 6: 1700cGy limited dose to liver, porta-hepatic, brain 1200cGy
170cGy BID Day 1-5.
Total dose 1700Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 7: 1800cGy limited dose to liver, porta-hepatic, brain 1200cGy
180cGy BID Day 1-5.
Total dose 1800Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 8: 1900cGy limited dose to liver, porta-hepatic, brain 1200cGy
190cGy BID Day 1-5.
Total dose 1900Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
Experimental: Level 9: 2000cGy limited dose to liver, porta-hepatic, brain 1200cGy
200cGy BID Day 1-5.
Total dose 2000Gy.
|
Given IV
Other Names:
Given IV
Other Names:
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Occurs approximately 48 hours after completion of cyclophosphamide
Undergo IMRT
Other Names:
Undergo IMRT using helical tomotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose of Intensity-modulated Radiotherapy (Phase I)
Time Frame: 30 days post transplant
|
Toxicities will be recorded using two distinct grading systems: the modified Bearman scale and the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 3.0 scale.
|
30 days post transplant
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Infection (Phase II)
Time Frame: 2 years post transplant
|
2 years post transplant
|
Acute and chronic graft-versus-host disease (Phase II)
Time Frame: 2 years post transplant
|
2 years post transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Anthony S. Stein, MD, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Leukemia, Lymphoid
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cyclophosphamide
- Etoposide
- Etoposide phosphate
Other Study ID Numbers
- 05021
- CHNMC-05021
- CDR0000579141 (Registry Identifier: NCI PDQ)
- NCI-2010-00427 (Registry Identifier: NCI CTRP)
- R01CA154491 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted